Novartis
NEWS
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.
Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.
Bancel reaped the rewards of SpikeVax’s success, but the Boston Business Journal noted that annual compensation for Moderna’s median employee plunged 16%.
Voyager has partnered with Novartis for the latter to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
A new market research report by InsightAce Analytic projects the immuno-oncology or cancer immunotherapy market will hit $34.69 billion by 2030.
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
GlaxoSmithKline unveiled plans for its new spinout in the consumer health division, Haleon. It is expected to be in place by mid-2022.
Prescription drug costs have continued to rise, with more than 150 drug manufacturers raising their prices in January.
The EUA request is based on the Phase II study that showed treatment with ensovibep reduced the viral load from the SARS-CoV-2 virus within eight days of use compared to placebo.
JOBS
IN THE PRESS